3 Takeaways As Fed. Circ. Limits Biosimilar Lawsuits
The Federal Circuit on Thursday averted potential chaos by not letting drugmakers use a wide variety of state laws to extract biosimilar manufacturing information from rivals, and its ruling will turn...To view the full article, register now.
Already a subscriber? Click here to view full article